Fortimedix Surgical closed a €11 million ($12.1 million) Series A, which it will put toward the U.S. and European launches of its single-port platform for laparoscopic surgery.
The device, dubbed FMX314, earned a CE mark and FDA clearance earlier this year. It is the first single-port surgery platform that is compatible with a standard 15 mm trocar for minimally invasive abdominal laparoscopic surgery, the company said in a statement. Because of this, it does not require a larger access incision that conventional multiport laparoscopy does.
FMX314 will reduce complications at the port site and postoperative pain while speeding up recovery. As the name suggests, single-port laparoscopy leaves only one scar, unlike traditional laparoscopy procedures.
The company will launch the device in the U.S. this month, while its European launch is slated for 2017. The Netherlands-based Chemelot Ventures led the round, with participation from existing shareholders, including MKB Leningenfonds and Rijksdienst voor Ondernemend Nederland.
“We are proud to partner with Fortimedix Surgical as it launches FMX314, which we believe can deliver on the promise of single-port laparoscopic surgery,” said Chemelot Ventures Managing Director Casper Bruens in the statement. “Since 2004 our firm has been involved with Fortimedix, a global leader in the field of endovascular stents, the company from which Fortimedix Surgical emerged in 2012. We have gained tremendous trust in the company’s leadership and are confident Fortimedix Surgical will achieve the ambitious commercial milestones for FMX314 as planned.”